Actively Recruiting
Randomized Comparison of Treosulfan Versus Melphalan Conditioning Chemotherapy with Post-Transplant Cyclophosphamide in Adults with AML and MDS Undergoing Allogeneic Stem Cell Transplantation
Led by Technische Universität Dresden · Updated on 2026-09-02
220
Participants Needed
17
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing the effects and tolerability of two chemotherapy conditioning treatments, Treosulfan and Melphalan, given before allogeneic stem cell transplantation in patients with Acute Myeloid Leukemia AML and Myelodysplastic Syndrome MDS. The study also looks at survival rates, remission and relapse, graft success or failure, and occurrences of Graft versus Host Disease GvHD. Participants receive either Treosulfan combined with Fludarabine from day -6 to day -2 or Melphalan combined with Fludarabine over the same period before transplantation. Both treatments are given intravenously, with specific dosing schedules Treosulfan at 10 gm2 on days -4 to -2, Melphalan at 140 mgm2 on day -2, and Fludarabine at 30 mgm2 from day -6 to day -2. GvHD prevention is planned with post-transplant cyclophosphamide PTCy on days 3 and 4. During the study, participants are monitored for overall survival up to two years after randomization. Researchers also assess relapse-free survival, non-relapse mortality, acute and chronic GvHD incidence, adverse events within 56 days post-transplant, engraftment rates, and remission status. Follow-up includes clinical and laboratory evaluations to understand treatment impact and safety over time.
CONDITIONS
Brief Title
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
Research Team
P
Prof. Friedrich Stölzel, MD
D
Desiree Kunadt, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here